Seres Therapeutics Net Worth
Seres Therapeutics Net Worth Breakdown | MCRB |
Seres Therapeutics Net Worth Analysis
Seres Therapeutics' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Seres Therapeutics' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Seres Therapeutics' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Seres Therapeutics' net worth analysis. One common approach is to calculate Seres Therapeutics' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Seres Therapeutics' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Seres Therapeutics' net worth. This approach calculates the present value of Seres Therapeutics' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Seres Therapeutics' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Seres Therapeutics' net worth. This involves comparing Seres Therapeutics' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Seres Therapeutics' net worth relative to its peers.
Enterprise Value |
|
To determine if Seres Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Seres Therapeutics' net worth research are outlined below:
| Seres Therapeutics is way too risky over 90 days horizon | |
| Seres Therapeutics has some characteristics of a very speculative penny stock | |
| Seres Therapeutics appears to be risky and price may revert if volatility continues | |
| Seres Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 126.33 M. Net Loss for the year was (113.72 M) with loss before overhead, payroll, taxes, and interest of (165.79 M). | |
| Seres Therapeutics currently holds about 195.8 M in cash with (117.35 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.58, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Seres Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Roughly 13.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from thelincolnianonline.com: Providence Wealth Advisors LLC Grows Stock Position in Seres Therapeutics, Inc. |
Seres Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Seres Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Seres Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 5th of March 2024 Upcoming Quarterly Report | View | |
| 14th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 5th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Seres Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Seres Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Seres Therapeutics backward and forwards among themselves. Seres Therapeutics' institutional investor refers to the entity that pools money to purchase Seres Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 342.2 K | Lion Point Capital, Lp | 2024-09-30 | 340.8 K | State Street Corp | 2024-06-30 | 339.5 K | Verition Fund Managegment, Llc | 2024-06-30 | 314.2 K | T. Rowe Price Associates, Inc. | 2024-06-30 | 267.4 K | Bridgeway Capital Management, Llc | 2024-09-30 | 250 K | Citigroup Inc | 2024-09-30 | 218.2 K | Northern Trust Corp | 2024-09-30 | 218.2 K | Ubs Group Ag | 2024-06-30 | 200.7 K | Flagship Ventures Management, Inc. | 2024-06-30 | 23.1 M | Fmr Inc | 2024-09-30 | 22.9 M |
Follow Seres Therapeutics' market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 167.32 M.Market Cap |
|
Project Seres Therapeutics' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.32) | (0.33) | |
| Return On Capital Employed | (0.42) | (0.44) | |
| Return On Assets | (0.32) | (0.33) | |
| Return On Equity | 2.54 | 2.66 |
When accessing Seres Therapeutics' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Seres Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Seres Therapeutics' profitability and make more informed investment decisions.
Please note, the presentation of Seres Therapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Seres Therapeutics' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Seres Therapeutics' management manipulating its earnings.
Evaluate Seres Therapeutics' management efficiency
Seres Therapeutics has return on total asset (ROA) of (0.097) % which means that it has lost $0.097 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (15.5628) %, meaning that it created substantial loss on money invested by shareholders. Seres Therapeutics' management efficiency ratios could be used to measure how well Seres Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Equity is expected to grow to 2.66, whereas Return On Tangible Assets are forecasted to decline to (0.33). At present, Seres Therapeutics' Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 53.5 M, whereas Total Assets are forecasted to decline to about 225.8 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | (0.35) | (0.33) | |
| Tangible Book Value Per Share | (0.35) | (0.33) | |
| Enterprise Value Over EBITDA | (3.10) | (3.26) | |
| Price Book Value Ratio | (4.00) | (3.80) | |
| Enterprise Value Multiple | (3.10) | (3.26) | |
| Price Fair Value | (4.00) | (3.80) | |
| Enterprise Value | 265.2 M | 251.9 M |
The strategic initiatives led by Seres Therapeutics' management are central to its market success. By analyzing these initiatives, we provide a clear picture of the stock's growth prospects.
Enterprise Value Revenue 1.5366 | Revenue 126.3 M | Quarterly Revenue Growth (0.93) | Revenue Per Share 0.871 | Return On Equity (15.56) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Seres Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Seres Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Seres Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Seres Therapeutics time-series forecasting models is one of many Seres Therapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Seres Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Seres Therapeutics Earnings per Share Projection vs Actual
Seres Therapeutics Corporate Management
| Jeff York | VP HR | Profile | |
| Carlo Tanzi | Head of Investor Relations and Corporate Communications | Profile | |
| SPHR SHRMSCP | Executive Officer | Profile | |
| RPh Young | Executive Officer | Profile | |
| Kristin Ainsworth | Sr Communications | Profile | |
| JD Esq | Executive Officer | Profile | |
| David Ege | Executive Officer | Profile |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Seres Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Seres Stock refer to our How to Trade Seres Stock guide.You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Seres Therapeutics. If investors know Seres will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Seres Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.40) | Revenue Per Share 0.871 | Quarterly Revenue Growth (0.93) | Return On Assets (0.1) | Return On Equity (15.56) |
The market value of Seres Therapeutics is measured differently than its book value, which is the value of Seres that is recorded on the company's balance sheet. Investors also form their own opinion of Seres Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Seres Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Seres Therapeutics' market value can be influenced by many factors that don't directly affect Seres Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Seres Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Seres Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Seres Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.